Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERMET: Metformin in Peripheral Artery Disease
NCT03054519Phase 3Completed
- Sponsor
- Northwestern University
- Start
- May 2017
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liquid metformin (Aspargo Labs) in peripheral artery disease (PAD) (2 arms), sponsored by Northwestern University. Primary endpoint: Six-minute Walk Performance at 6 months. Started May 2017; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT03054519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03054519.